9 Meters CEO resigns; interim CEO appointed; vurolenatide Phase 2 trial planned

9 METERS BIOPHARMA, INC.

CEO John Temperato resigns effective May 26, 2023; Bethany Sensenig (CFO) named interim CEO.
Separation agreement includes 12 months base salary, pro-rated 2023 bonus, and 12 months equity vesting extension.
Company revises vurolenatide plan: additional Phase 2 trial for SBS instead of Phase 3, subject to funding availability.
Company continues to assess strategic alternatives; trial timing depends on securing funding.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Temperato

Chief Executive Officer

9 METERS BIOPHARMA, INC.

Effective: 2023-05-26
Successor: Bethany Sensenig
Filed: May 30, 2023, 7:59 PM ET

John Temperato, the Chief Executive Officer (the “CEO”) and a Class II director on the Board of Directors (the “Board”) of 9 Meters Biopharma, Inc. (the “Company”) resigned from his role as CEO and director of the Company, effective at the close of business on May 26, 2023.

Appointed (interim)

Bethany Sensenig

Interim Chief Executive Officer

9 METERS BIOPHARMA, INC.

Filed: May 30, 2023, 7:59 PM ET

The Board appointed Bethany Sensenig, Chief Financial Officer of the Company, to serve as Interim Chief Executive Officer, and principal executive officer for SEC purposes, of the Company, in addition to her current responsibilities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Temperato resigned as Chief Executive Officer at 9 METERS BIOPHARMA, INC..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

John Temperato, the Chief Executive Officer (the “CEO”) and a Class II director on the Board of Directors (the “Board”) of 9 Meters Biopharma, Inc. (the “Company”) resigned from his role as CEO and director of the Company, effective at the close of business on May 26, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bethany Sensenig was appointed as Interim Chief Executive Officer at 9 METERS BIOPHARMA, INC..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

The Board appointed Bethany Sensenig, Chief Financial Officer of the Company, to serve as Interim Chief Executive Officer, and principal executive officer for SEC purposes, of the Company, in addition to her current responsibilities.

View on SEC.gov

Source: SEC EDGAR

accession 0001551986-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.